Review demonstrates that GlycA tracks systemic and subclinical vascular inflammation in chronic inflammatory conditions, suggesting potential utility for evaluating cardiovascular disease risk.
Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits.
No takes yet. Share an insight, caveat, or question.
Connelly et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: